Clearpoint Neuro (CLPT) Q3 2025 earnings summary

Executive summary

• Announced a strategic merger agreement to acquire IRRAS Holdings, Inc., expanding into neurocritical care and cranial irrigation markets, and enhancing operational scale with a combined commercial team of over 50 professionals.

• Revenue for Q3 2025 increased 9% year-over-year to $8.9 million, driven by growth in service revenue and neurosurgery navigation and therapy sales.

• Supported over 60 biopharma partners, with nine programs accepted for FDA expedited review and expanded global regulatory clearances to 34 countries.

• Transitioned to a dual strategy: "fast forward" (penetrating existing markets) and "essential everywhere" (building a new neurodrug delivery market with pharma partners).

• Demonstrated a prototype Robotic Neuro-Navigation System and received FDA clearance for PRISM Laser Therapy System compatibility with 1.5T MRI.

Financial highlights

• Q3 2025 revenue was $8.9 million, up 9% year-over-year from $8.1 million in Q3 2024.

• Gross margin improved to 63% from 60% in the prior year, driven by higher service margins and favorable product mix.

• Net loss for Q3 2025 was $5.9 million, compared to $5.0 million in Q3 2024; net loss per share was $(0.21).

• Cash and equivalents stood at $38.2 million as of September 30, 2025, up from $20.1 million at year-end 2024, reflecting $32 million in new financing offset by $11.8 million in operating cash use.

• Operating expenses increased 9% to $10.9 million, driven by R&D, professional services, and personnel costs.

Outlook and guidance

• 2025 full-year revenue forecast narrowed to $36–38 million, consistent with prior guidance.

• Combined 2026 revenue for the company and IRRAS expected to be $54–60 million, subject to integration and other risks.

• Biologics and drug delivery segment expected to return to double-digit growth in Q4 2025 and accelerate in 2026–2027.

• Management expects continued growth in neurosurgery navigation and biologics/drug delivery segments, with more than 60 partners as of Q3 2025.

• Cash reserves are projected to be sufficient to support operations for at least the next twelve months.